Sun Pharmaceutical Industries announced on Friday that its subsidiary has been given the go-ahead to market a generic medication for the treatment of multiple myeloma by the US health regulator.
According to a statement from Sun Pharma, the US Food and Drug Administration (USFDA) has given the company final approval for the generic lenalidomide capsules in multiple strengths. Sun Pharma and Celgene Corporation (Celgene) reached a settlement in June 2021 to end the legal dispute over the patent for Sun Pharma’s generic lenalidomide capsules.
In accordance with the settlement’s terms, Celgene gave Sun Pharma a licence to the patents necessary to produce and market a specific number of generic lenalidomide capsules in the US, starting sometime after March 2022.
In addition, starting on January 31, 2026, the licence enables Sun Pharma to produce and market an unlimited number of generic lenalidomide capsules in the US. On the BSE, Sun Pharma shares were down 0.48 percent, trading at Rs 1,002 per share.